0.240
-0.01 (-3.96%)
| Penutupan Terdahulu | 0.250 |
| Buka | 0.251 |
| Jumlah Dagangan | 294,671 |
| Purata Dagangan (3B) | 1,050,905 |
| Modal Pasaran | 63,638,984 |
| Harga / Jualan (P/S) | 0.330 |
| Harga / Buku (P/B) | 2.68 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2025 - 16 Aug 2025 |
| Margin Keuntungan | -38.91% |
| Margin Operasi (TTM) | -604.96% |
| EPS Cair (TTM) | -0.300 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 28.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 626.29% |
| Nisbah Semasa (MRQ) | 2.02 |
| Aliran Tunai Operasi (OCF TTM) | -107.85 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -30.50 M |
| Pulangan Atas Aset (ROA TTM) | -14.19% |
| Pulangan Atas Ekuiti (ROE TTM) | -275.74% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Adaptimmune Therapeutics plc | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.88 |
|
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 0.63% |
| % Dimiliki oleh Institusi | 44.16% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 1.00 (Wells Fargo, 316.49%) | Pegang |
| Median | 0.500 (108.25%) | |
| Rendah | 0.460 (Barclays, 91.59%) | Jual |
| Purata | 0.653 (171.97%) | |
| Jumlah | 2 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 0.262 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Mizuho | 26 Jun 2025 | 0.500 (108.25%) | Pegang | 0.242 |
| Barclays | 14 May 2025 | 0.460 (91.59%) | Jual | 0.272 |
| Wells Fargo | 14 May 2025 | 1.00 (316.49%) | Pegang | 0.272 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 May 2025 | Pengumuman | Adaptimmune Reports Q1 Financial Results and Provides Business Update |
| 07 May 2025 | Pengumuman | Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |